results of n-803, an il-15rαfc superagonist, with bcg in bcg-unresponsive cis and nmibc
Published 2 years ago • 377 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
3:17
n-803-bcg combination shows promising results in bcg-unresponsive nmibc
-
5:24
nmibc treated with il-15rαfc superagonist n-803 and bcg infusion
-
11:45
emerging treatments for bcg unresponsive non-muscle invasive bladder cancer
-
1:55
durvalumab monotherapy for patients with bcg-unresponsive carcinoma-in-situ bladder cancer
-
50:41
management of bcg-unresponsive non-muscle invasive bladder cancer
-
10:35
management of bcg unresponsive cystectomy ineligible bladder cancer patients pembrolizumab
-
36:09
bladder cancer 2022
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
29:46
introduction to adstiladrin | gene therapy for bcg unresponsive nmibc
-
2:38
impact of re-tur on bcg-treated t1 hg/g3 bladder cancer
-
0:38
what are the symptoms of advanced bladder cancer? by dr. cory hugen - uci department of urology
-
0:39
predicting immunotherapy response in bladder cancer
-
4:47
tnbc: updated efficacy results from impassion130
-
2:12
the rationale behind the phase iii trial on neoadjuvant intravesical mmc treatment of bladder cancer
-
1:54
innovations in treatment options for patients with bcg-unresponsive urothelial carcinoma
-
1:45
diagnosing g3 nets and necs
-
3:57
overview of prospective phase 3 planb trial of 21-gene recurrence score® result in breast cancer
-
7:09
introduction: review of guideline updates
-
6:19
case 4_contrast enhancement eus and eus guided fine needle aspiration of large abdominal gist
-
2:10
dr. langer on the benefit of durvalumab in stage iii nsclc
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
3:38
results of phase iii gadolin trial for follicular lymphoma